These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
484 related articles for article (PubMed ID: 25437093)
1. Association of cerebrospinal fluid levels of lateral olfactory tract usher substance (LOTUS) with disease activity in multiple sclerosis. Takahashi K; Kurihara Y; Suzuki Y; Goshima Y; Tanaka F; Takei K JAMA Neurol; 2015 Feb; 72(2):176-9. PubMed ID: 25437093 [TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis. Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369 [TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid level of Nogo receptor 1 antagonist lateral olfactory tract usher substance (LOTUS) correlates inversely with the extent of neuroinflammation. Takahashi K; Takeuchi H; Kurihara Y; Doi H; Kunii M; Tanaka K; Nakamura H; Fukai R; Tomita-Katsumoto A; Tada M; Higashiyama Y; Joki H; Koyano S; Takei K; Tanaka F J Neuroinflammation; 2018 Feb; 15(1):46. PubMed ID: 29454354 [TBL] [Abstract][Full Text] [Related]
4. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis. Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573 [TBL] [Abstract][Full Text] [Related]
5. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. Ottervald J; Franzén B; Nilsson K; Andersson LI; Khademi M; Eriksson B; Kjellström S; Marko-Varga G; Végvári A; Harris RA; Laurell T; Miliotis T; Matusevicius D; Salter H; Ferm M; Olsson T J Proteomics; 2010 Apr; 73(6):1117-32. PubMed ID: 20093204 [TBL] [Abstract][Full Text] [Related]
6. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691 [TBL] [Abstract][Full Text] [Related]
7. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. Öhrfelt A; Axelsson M; Malmeström C; Novakova L; Heslegrave A; Blennow K; Lycke J; Zetterberg H Mult Scler; 2016 Oct; 22(12):1587-1595. PubMed ID: 26754805 [TBL] [Abstract][Full Text] [Related]
8. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354 [TBL] [Abstract][Full Text] [Related]
11. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy. Elovaara I; Ukkonen M; Leppäkynnäs M; Lehtimäki T; Luomala M; Peltola J; Dastidar P Arch Neurol; 2000 Apr; 57(4):546-51. PubMed ID: 10768630 [TBL] [Abstract][Full Text] [Related]
12. Increased cerebrospinal fluid tau protein in multiple sclerosis. Kapaki E; Paraskevas GP; Michalopoulou M; Kilidireas K Eur Neurol; 2000; 43(4):228-32. PubMed ID: 10828654 [TBL] [Abstract][Full Text] [Related]
13. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders. Komori M; Matsuyama Y; Nirasawa T; Thiele H; Becker M; Alexandrov T; Saida T; Tanaka M; Matsuo H; Tomimoto H; Takahashi R; Tashiro K; Ikegawa M; Kondo T Ann Neurol; 2012 May; 71(5):614-23. PubMed ID: 22522477 [TBL] [Abstract][Full Text] [Related]
14. [Axonal Regeneration-related Molecules as Biomarkers for Multiple Sclerosis]. Takahashi K; Tanaka F; Takei K Brain Nerve; 2016 Jan; 68(1):82-9. PubMed ID: 26764302 [TBL] [Abstract][Full Text] [Related]
15. Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice. Cristofanilli M; Rosenthal H; Cymring B; Gratch D; Pagano B; Xie B; Sadiq SA Exp Neurol; 2014 Nov; 261():620-32. PubMed ID: 25111532 [TBL] [Abstract][Full Text] [Related]
16. The carboxyl-terminal region of Crtac1B/LOTUS acts as a functional domain in endogenous antagonism to Nogo receptor-1. Kurihara Y; Arie Y; Iketani M; Ito H; Nishiyama K; Sato Y; Nakamura F; Mizuki N; Goshima Y; Takei K Biochem Biophys Res Commun; 2012 Feb; 418(2):390-5. PubMed ID: 22281491 [TBL] [Abstract][Full Text] [Related]
17. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Guimarães I; Cardoso MI; Sá MJ Mult Scler; 2006 Jun; 12(3):354-6. PubMed ID: 16764350 [TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis. Burman J; Svenningsson A J Neuroimmunol; 2016 Mar; 292():40-4. PubMed ID: 26943957 [TBL] [Abstract][Full Text] [Related]
20. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis. Avsar T; Korkmaz D; Tütüncü M; Demirci NO; Saip S; Kamasak M; Siva A; Turanli ET Mult Scler; 2012 Aug; 18(8):1081-91. PubMed ID: 22252467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]